Lipitor

Atorvastatin, the active ingredient in Lipitor, is a HMG‑CoA reductase inhibitor presented as a tablet for oral use. It treats hypercholesterolemia, mixed dyslipidemia and helps reduce cardiovascular risk in adult patients.

GNH USA supplies Lipitor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Atorvastatin acts on lipid metabolism disorders and is indicated for several cardiovascular‑related conditions. - Hypercholesterolemia: lowers LDL‑cholesterol and total cholesterol levels. - Mixed dyslipidemia: reduces triglycerides and raises HDL‑cholesterol. - Primary prevention of cardiovascular events: decreases the risk of myocardial infarction, stroke and related complications in patients with established risk factors.

Adverse reactions may occur with atorvastatin therapy.

Common Side Effects: - Muscle pain or weakness - Headache - Nausea - Abdominal discomfort - Constipation - Elevated liver enzymes

Serious or Rare Side Effects: - Rhabdomyolysis - Severe liver injury - Allergic reactions (rash, angioedema) - Myopathy with marked CK elevation - Acute kidney injury - Stevens‑Johnson syndrome

Before initiating therapy, consider the following safety measures. - Monitor liver function: obtain baseline and periodic hepatic enzyme tests. - Assess renal function: adjust dosing in severe impairment. - Review concomitant medications: avoid strong CYP3A4 inhibitors. - Counsel on muscle symptoms: discontinue if unexplained myalgia with CK rise. - Pregnancy and lactation: contraindicated unless benefits outweigh risks. - Store at room temperature: keep in the original container, protect from moisture and heat.

Atorvastatin may interact with several drug classes; careful assessment is required.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase statin exposure. - Grapefruit juice: raises plasma concentration. - Cyclosporine: heightened risk of myopathy. - HIV protease inhibitors: elevate atorvastatin levels. - High‑dose colchicine: risk of toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may enhance anticoagulant effect. - Fibrates (gemfibrozil): increased muscle toxicity risk. - Niacin: additive liver enzyme elevation. - Antidiabetic agents (sulfonylureas): possible glucose control changes. - Beta‑blockers: monitor for additive cardiovascular effects.